PIPA520759
MC4R Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA520759-Each-of-1 | In Stock | ₹ 49,350.50 |
PIPA520759 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 49,350.50
GST (18%): ₹ 8,883.09
Total Price: ₹ 58,233.59
Antigen
MC4R
Classification
Polyclonal
Conjugate
Unconjugated
Gene
MC4R
Gene Alias
MC4; MC4 receptor; mc4r; Mc4-r; melanocortin 4 receptor; melanocortin receptor 4; si:dkey-151m6.62; zMC4
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
17202, 25635, 4160
Content And Storage
Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C
Form
Liquid
Applications
Immunohistochemistry, Western Blot
Concentration
1 mg/mL
Formulation
PBS with 0.02% sodium azide
Gene Accession No.
P32245, P56450, P70596
Gene Symbols
MC4R
Immunogen
A 19 amino acid peptide near the amino terminus of human MC4R.
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG
Related Products
Description
- A suggested positive control is rat brain tissue lysate
- PA5-20759 can be used with blocking peptide PEP-0873
- Expression of MC4R has been reported in brain
- Unlike the other melanocortin receptors, MC4R is not expressed in adrenal cortex or in melanocytes
- G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist
- All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms
- An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors
- Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs
- This "eturn-off"e activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates
- Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.